Eli Lilly Sues Six Companies Over Black-Market Weight Loss Drug

Eli Lilly, the major pharmaceutical company, has initiated six legal actions against U.S. firms accused of unlawfully distributing black-market versions of its experimental weight loss medication, retatrutide. These lawsuits, submitted on Wednesday, focus on businesses that have promoted and sold the unapproved drug to consumers. Since retatrutide lacks approval from any regulatory body for human consumption, its sale is deemed illegal. This legal initiative highlights the escalating issue of counterfeit and unauthorized weight loss medications, especially as demand for such solutions rises. Eli Lilly's actions seek to safeguard patient safety and protect its intellectual property. While the specific names of the sued companies remain undisclosed, these lawsuits form part of a wider strategy to tackle the spread of unapproved drugs.